Authorised Indian Distributor
Saxsons Group
New Delhi, India · Since 1997
A reusable beryllium-oxide optically stimulated luminescent dosimeter for clinical radiotherapy. The myOSL Chip pairs a 4.7 × 4.7 × 0.5 mm BeO element with an ABS light-tight housing — a small, MR-safe, reusable detector that fits the same workflows as the discontinued Landauer nanoDot. Validated in two 2025 peer-reviewed studies for in-vivo dosimetry, TBI, TSET, electrons and out-of-field measurements.
| Detector material | Beryllium oxide (BeO), Z_eff 7.21, density 2.85 g/cm³ |
| Element dimensions | 4.7 × 4.7 × 0.5 mm |
| Housing | 9.5 × 10 × 2 mm ABS light-tight enclosure |
| Dose range (validated) | 0.1 – 20 Gy |
| Linearity correction | −0.5% to +3% across 0.1–20 Gy (Kowalski 2025) |
| Dose-rate dependence | None across 100–2500 MU/min |
| Energy response (photon) | −4.5% (2.5 MV FFF) to +4.5% (15 MV), relative to 6 MV |
| Energy response (electron) | +1.9% (6 MeV) to +4.3% (20 MeV) |
| Angular response | −2.02% ± 0.45% at 90° vs en-face (6 MV) |
| Signal depletion / read | −2.13% ± 0.20% average per read-out |
| Element sensitivity drift | ~−2% from 0–15 Gy cumulative, then stable to 32 Gy |
| MR safety | MR-safe (no metallic components) |
| Compatible reader | myOSLchip handheld reader / eraser |
| Applications | In-vivo dosimetry, TBI, TSET, electrons, out-of-field, pacemaker dose checks, research |
In-vivo dosimetry — one detector, many techniques
Entrance- or exit-dose verification during external-beam radiotherapy. Validated against AAPM TG-191 in 2025 clinical commissioning studies.
Davis 2025 demonstrated equal-or-better performance vs Landauer nanoDot in total-body irradiation and total-skin electron therapy in-vivo measurements.
Out-of-field dose verification at implanted device locations — small form factor places the dosimeter at the device without distorting the treatment.
Low-dose tail measurements outside the treatment field. BeO's Z_eff and small form factor make it a natural fit for organ-at-risk in-vivo points.
Validated for 6–20 MeV electrons. En-face placement on superficial targets — common in head-and-neck and skin treatments.
Independent dose verification for new IMRT/VMAT plans or research protocols. Reusable detectors keep per-measurement cost low.
Beryllium oxide has a Z_eff of 7.21 and density of 2.85 g/cm³, closer to tissue than Al2O3:C-based dosimeters. That translates to less energy-dependent correction across the photon and electron beams used in modern radiotherapy.
The Kowalski 2025 and Davis 2025 papers commissioned the myOSLchip against AAPM TG-191 — the same protocol clinics already use for OSL in-vivo dosimetry. No re-design needed; calibration factors are characterised across photon (2.5 MV FFF to 15 MV) and electron (6–20 MeV) beams.
Beam-quality correction kQ ranges from −4.5% at 2.5 MV FFF to +4.5% at 15 MV (relative to 6 MV). Dose-rate response is flat across 100–2500 MU/min — covering both conventional and FFF treatment deliveries.
Manufacturer datasheets and ordering information. Peer-reviewed validation papers are on the Knowledge Hub — link above.
myOSL™ Chip
Each card opens a focused post for a specific specialty — peer-reviewed evidence and clinical workflow, written for the persona you select.
For Medical Physicist
Linearity to 10 Sv, fading at 3 months, energy & angular response — the manufacturer type-test data in one page.
Read this Medical PhysicistMOSFETs need replacement every 200–400 Gy and most readers max out at 5 channels per module. What changes when you switch to BeO OSL?
Read this Medical PhysicistTBI needs 8–10+ in-vivo points across a long fraction. Where does the myOSL Chip line up with the workflow — and what does the peer-reviewed evidence say?
Read thisContact Saxsons Group for pricing on the myOSL Chip dosimeter (DM-005), the myOSLchip handheld reader, demo arrangement, AERB import documentation and installation support.